Multiple sclerosis (MS) pathology is marked by the massive infiltration of myelin-specific T cells into the central nervous system (CNS). During active disease, pro-inflammatory Th1/Th17 cells predominate over immunoregulatory Th2/Treg cells. Here, we show that calpain inhibition downregulates Th1/Th17 inflammatory cytokines and mRNA in MS patient peripheral blood mononuclear cells (PBMCs) activated with anti-CD3/28 or MBP. Interestingly, calpain inhibition elevated IDO gene expression in MS PBMCs, which was markedly decreased in calpain expressing cells. Functional assay showed that incubation of MS patient PBMCs with calpain inhibitor or recombinant IDO attenuates T cell proliferation. These results suggest that calpain inhibition may attenuate MS pathology and augment the efficacy of standard immunomodulatory agents used to treat this disease.
Introduction
Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system (CNS) with clinical symptoms including fatigue, paralysis, and visual dysfunction (Williams et al., 1994) . There are 250,000-350,000 people with MS in the United States, and it is the leading cause of neurologic disability in early-to-middle adulthood (Anderson et al., 1992) . Increased activity and expression of the Ca 2+ -activated protease, calpain, have been detected in CNS tissue, immune cells of MS patients, and in the corresponding animal model, experimental allergic encephalomyelitis (EAE) (Banik, 1992; Cuzner et al., 1975; Guyton et al., 2005; Hassen et al., 2006; Shields et al., 2000; Shields and Banik, 1998) . The calpains are a family of at least 15 cysteine proteases that are activated at neutral conditions in the cells by Ca 2+ (Wu et al., 2007) . Both ubiquitous and tissue-specific calpains have been identified which play roles in many molecular processes including cell proliferation and differentiation, T cell activation (Cuzzocrea et al., 2000; Schaecher et al., 2002) , immune cell migration (Butler et al., 2009 ), signal transduction (Kanungo et al., 2009 ), necrosis (Gill and Perez-Polo, 2009 , and apoptosis (Colak et al., 2009; Guyton et al., 2005) .
The activation of myelin-specific T cells is thought to be a major event in MS disease development and progression. Production of proinflammatory Th1 cytokines (e.g. TNFα, IL-2, and IFNγ) by CD4 + T cells is increased in MS patients during an exacerbation (Kivisakk et al., 2003; Lassmann and Ransohoff, 2004) . In contrast, anti-inflammatory Th2 cytokines (e.g. IL-4, IL-10, and IL-13) are predominant during disease remission (Issazadeh et al., 1995; Kennedy et al., 1992) . We have determined that calpain expression and activity are increased in activated peripheral blood mononuclear cells (PBMCs) during MS disease exacerbations, and inhibition of calpain in these cells attenuates secretion of IL-2 and IFNγ, thus promoting an anti-inflammatory cytokine bias (Imam et al., 2007) . Calpain is involved in T cell activation through direct modulation of signaling proteins that lead to cytokine production (Hendry and John, 2004; Schaecher et al., 2004) . Also, an indirect modulation of T cell activity by calpain, via cleavage of myelin protein into antigenic peptides that could activate myelin basic protein specific T cells, (Deshpande et al., 1995; Imam et al., 2007; Medveczky et al., 2006; Schaecher et al., 2001 ) has been observed. An important consequence of T cell activation is the induction of transcription factor nuclear factor kappa-B (NFκB), which is regulated by its inhibitors, IκBα and IκBβ (Baldwin, 1996) . In turn, pro-inflammatory NFκB further activates T lymphocytes via production of IL-2 and CD25 (Algarte et al., 1995; Gerondakis et al., 1998; Zuckerman et al., 1998) . The cellpermeable calpain inhibitor, calpeptin, inhibits IκBα degradation in a time and dose-dependent manner, through direct interaction with calpain-cleavage sites on the IκBα protein (Schaecher et al., 2004) . Since Th1/Th2 cytokines differentially regulate chemokine signaling, the effect of calpain activity on migration of immune cells toward Journal of Neuroimmunology 232 (2011) 179-185 
